Collectively, the gain-of-function, loss-of-function, and patient-derived data all suggested that TIA1 condensates may constitute the molecular switch that couples BCG exposure to tumor cell glycolytic repression and revitalization of CD8+ T cell anti-tumor immunity. This evidence concerns the gene CD8A and neoplasm.